Clarus Group, Inc. Eli Lilly & CO Transaction History

Clarus Group, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$525.19 - $619.13 $4,201 - $4,953	-8 Reduced 0.48%	1,644 $958,000
Q2 2023 Jul 17, 2023	BUY	$350.74 - $468.98 $18,238 - $24,386	52 Added 3.25%	1,652 $774,000
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $5,397 - $6,708	-23 Reduced 1.42%	1,600 $458,000
Q1 2021 May 07, 2021	BUY	$164.32 - $212.72 $266,691 - $345,244	1,623 New	1,623 $296,000
Q1 2021 Apr 16, 2021	SELL	$164.32 - $212.72 $266,691 - $345,244	-1,623 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $211,736 - $280,178	1,623 New	1,623 $336,000

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Clarus Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Clarus Group, Inc. with notifications on news.